Work

Hugo RAS versus da Vinci Xi for robot-assisted simple hysterectomy in endometrial cancer: a concurrent-period comparison of operative efficiency, cost structure, and the cost of early adoption

Year: 2026
Type: article
Study design: Observational Study
Abstract: Assessing a newly introduced robotic platform is complicated by structural confounding between platform and calendar time, which makes device-specific performance hard to separate from early-adoption learning. We compared the Hugo robotic-assisted surgery (RAS) system with the da Vinci Xi in robot-assisted simple hysterectomy for endometrial cancer, confining the primary analysis to the period of concurrent use of the two platforms. This single-centre retrospective cohort included 219 patients with clinical stage I endometrial cancer operated between May 2018 and November 2025; procedures involving lymphadenectomy or sentinel lymph node biopsy were excluded at eligibility so that operative time remained comparable. The Hugo RAS was introduced on 4 December 2023, and the standardised mean difference (SMD) for operative month across the full period was 2.10; the primary analysis was therefore limited to 67 concurrent-period procedures (da Vinci Xi 37, Hugo RAS 30; SMD 0.66). Time outcomes were modelled by linear regression and cost outcomes by gamma regression with a log link, both with robust standard errors. In the concurrent period, the adjusted mean difference in total operative time was 16.3 min (95% confidence interval [CI] 6.0–26.6; p = 0.002), falling to 6.1 min (95% CI − 0.7 to 13.0; p = 0.080) when the first ten Hugo RAS procedures were excluded. Adjusted cost ratios favoured the Hugo RAS for consumables (0.808) and total operative cost (0.923), with no clear difference in reimbursement (1.013). The attenuation after excluding early cases points to an early-adoption contribution that cannot be separated from platform effects.
Language: English
Open Access status: green
OpenAlex ID: W7221827018
FWCI:
Cites: 20
Cited by:
Related to: 10